Shares in biotech Pharmaxis go nuts on the $750 million sale of a liver drug

Oli Scarff/Getty Images

Australian biotech Pharmaxis has sold a drug to treat a common liver disease to a German company in a deal worth $750 million.

The drug, called PXS4728A, is designed to treat NASH, a progressive form of non‐alcoholic fatty liver disease, the most common liver disorder in Western nations.  It is regarded as a major cause of fibrosis and cirrhosis of the liver.

CEO Gary Phillips says the deal with Boehringer Ingelheim has a total potential value of more than $750 million.

Pharmaxis will receive an upfront payment of Euro 27.5 million (approximately $39 million) and further payments over time, subject to the continuing successful development and commercialisation of PXS4728A.

It’s shares were trading almost 50% higher at $0.247.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.